清热化痰益气散结方用于治疗晚期非小细胞肺癌抗肿瘤效果  

Anti-tumor Effect of Qingre Huatan Yiqi Sanjie Prescription in Advanced Non-small Cell Lung Cancer

作　　者：赵志飞 于梦 孙军娜 王孟超 ZHAO Zhifei;YU Meng;SUN Junna;WANG Mengchao(Tianjin Beichen Hospital of Traditional Chinese Medicine,Tianjin 300400,China;The First Affiliated Hospital of Tianjin University of Chinese Medicine,Tianjin 300400,China)

机构地区：[1]天津市北辰区中医医院,天津300400 [2]天津中医药大学第一附属医院,天津300400

出　　处：《中国医药导刊》2025年第2期182-186,共5页Chinese Journal of Medicinal Guide

基　　金：天津市北辰区科技计划项目(SHGY-2022014)。

摘　　要：目的:观察清热化痰益气散结方用于治疗晚期非小细胞肺癌(NSCLC)的抗肿瘤效果,以及对血清基质金属蛋白酶9(MMP-9)、血管内皮生长因子(VEGF)的影响。方法:选取2022年3月至2024年6月我院收治的晚期NSCLC患者共120例,利用随机数字表法分为观察组与对照组,每组各60例。对照组患者采用常规TP化疗方案,观察组患者在TP化疗方案上辅助应用清热化痰益气散结方,两组患者均持续治疗4个周期(1个周期21 d)。比较两组患者的近期临床疗效、证候积分、血清肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、MMP-9和VEGF]水平和不良反应。结果:观察组患者疾病总缓解率高于对照组(P<0.05);观察组患者治疗4个周期后证候积分低于对照组(P<0.05)。治疗后,两组患者血清CEA、CYFRA21-1、MMP-9、VEGF水平较治疗前均下降(P<0.05),且观察组患者各指标水平下降幅度均优于对照组(P<0.05)。观察组患者骨髓抑制发生率低于对照组(P<0.05)。结论:清热化痰益气散结方在晚期NSCLC的治疗中具有良好的抗肿瘤效果,并能有效改善患者的中医证候积分,降低血清MMP-9和VEGF水平,减轻化疗不良反应。Objective:To observe the anti-tumor effect of qingre huatan yiqi sanjie prescription and its influences on serum matrix metalloproteinase-9(MMP-9)and vascular endothelial growth factor(VEGF)in advanced non-small cell lung cancer(NSCLC).Methods:120 patients with advanced NSCLC in our hospital from March 2022 to June 2024 were selected and divided into the control group(routine TP chemotherapy)and the observation group(qingre huatan yiqi sanjie prescription on basis of the control group accord-ing to random number table method treatment),with 60 cases in each group.All patients were treated for 4 cycles(21 d/cycle).The short-term clinical curative effect,scores of syndromes,levels of serum tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),MMP-9 and VEGF],and adverse reactions were compared between the two groups.Results:The total remission rate of disease in the observation group was higher than that in the control group(P<0.05).After 4 cycles of treatment,scores of syndromes in the observation group were lower than those in the control group(P<0.05).After treatment,levels of serum CEA,CYFRA21-1,MMP-9 and VEGF,were lower in both groups than before treatment(P<0.05),and the decrease of each index in the observation group was better than that in the control group(P<0.05).The incidence of myelosuppression in the observation group was lower than that in the control group(P<0.05).Conclusion:Qingre huatan yiqi sanjie prescription has good anti-tumor effect in the treat-ment of advanced NSCLC,which can effectively improve TCM syndromes scores,reduce serum MMP-9 and VEGF levels,and alleviate adverse reactions of chemotherapy.

关 键 词：晚期非小细胞肺癌 清热化痰益气散结方 抗肿瘤 基质金属蛋白酶9 血管内皮生长因子 

分 类 号：R273[医药卫生—中西医结合] R734.2[医药卫生—中医肿瘤科]